Effects of L-Theanine and Hericium Erinaceus Gummies on Psychological, Cognitive, and Sleep Quality in University Students (THEA-HEAL)
Effects of L-Theanine and Hericium Erinaceus-Enriched Gummies on Psychological, Cognitive, and Sleep Quality in University Students: An 8-Week Randomized Controlled Trial (THEA-HEAL Trial)
The THEA-HEAL Trial is an 8-week randomized controlled study investigating the effects of a daily gummy supplement containing L-theanine and Hericium erinaceus (Lion's mane mushroom) extract on stress, anxiety, cognitive performance, and sleep quality in university students in Malaysia. University life can be a stressful period associated with increased psychological distress, sleep problems, and difficulty concentrating.
In this study, eligible participants aged 18-25 years were randomly assigned to either receive the active gummy supplement or no supplementation. The intervention group consumed gummies twice daily, providing a total daily dose of 180 mg L-theanine and 300 mg H. erinaceus extract.
The main purpose of the study is to determine whether this nutraceutical combination can help reduce stress and anxiety and improve cognitive function and sleep quality compared with no supplementation. Additional outcomes include physical activity levels and dietary intake. Findings from this study may provide evidence on the potential role of functional food-based supplements in supporting mental well-being and cognitive health in young adults.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Semenyih, Maleisië
- University of Nottingham Malaysia
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Malaysian male and female university students aged 18-25 years
- Reporting moderate levels of stress and/or anxiety
- Not regularly using cognitive-enhancing supplements in the past 3 months
Exclusion Criteria:
- Pregnancy or breastfeeding
- Presence of chronic medical conditions that could affect study outcomes
- Substance abuse or high caffeine intake (>400 mg/day)
- Current use of medications or supplements that may influence stress or cognitive function (e.g., antidepressants or nootropics) in the past 3 months
- Known allergies or hypersensitivity to L-theanine or Hericium erinaceus
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Gummy Intervention
Intervention group consumed six gummies daily for 8 weeks (180 mg L-theanine and 300 mg H. erinaceus extract)
|
Intervention group consumed six gummies daily for 8 weeks.
Each gummy contained 30 mg of L-theanine and 50 mg of H. erinaceus extract, corresponding to a total daily intake of 180 mg L-theanine and 300 mg H. erinaceus extract.
|
|
Geen tussenkomst: control
Not receiving gummy
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Psychological assessment
Tijdsspanne: baseline and post-intervention (week 0 and week 8)
|
Psychological outcomes were evaluated using the 21-item Depression, Anxiety, and Stress Scale (DASS-21) Scores for each subscale range from 0 to 21, with higher scores indicating greater levels of depression, anxiety, and stress (i.e., worse psychological outcomes).
|
baseline and post-intervention (week 0 and week 8)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Body weight
Tijdsspanne: Baseline and post intervention (week 0 and week 8)
|
Body weight was measured using a calibrated digital weighing scale (Inbody 230, South Korea) to the nearest 0.1 kg.
Participants were instructed to remove shoes, heavy clothing, and personal items prior to measurement.
Body mass index (BMI) was derived using the formula body weight (kg) divided by height squared (m2).
|
Baseline and post intervention (week 0 and week 8)
|
|
Height
Tijdsspanne: Baseline and post-intervention (week 0 and week 8)
|
Height was measured using a portable stadiometer (SECA 213, Germany) to the nearest 0.1 cm.
Height was assessed with participants standing upright, heels together, arms relaxed at the sides, and head positioned in the Frankfort horizontal plane.
Body mass index (BMI) was derived using the formula body weight (kg) divided by height squared (m2).
|
Baseline and post-intervention (week 0 and week 8)
|
|
Sleep quality
Tijdsspanne: baseline and post intervention (week 0 and week 8)
|
Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI).
The questionnaire consists of 19 self-rated items that assess seven components: subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbance, use of medication and daytime dysfunction.
Each component is scored from 0 to 3, yielding a global score ranging from 0 to 21, with higher scores indicating poorer sleep quality.
A global score >5 indicated poor sleep quality.
|
baseline and post intervention (week 0 and week 8)
|
|
Physical activity
Tijdsspanne: baseline and post-intervention (week 0 and week 8)
|
Physical activity levels were assessed using the International Physical Activity Questionnaire - Short Form. The questionnaire contains seven items quantifying the frequency (days per week) and duration (minutes per day) of walking, moderate-intensity activity, vigorous-intensity activity, and sedentary behaviour. Responses were converted into metabolic equivalent task (MET)-minutes per week according to standardized IPAQ scoring guidelines. Participants were categorized into low (<600 MET-min/week), moderate (600-3000 MET-min/week), and high (>3000 MET-min/week) physical activity levels. |
baseline and post-intervention (week 0 and week 8)
|
|
Dietary intake assessment
Tijdsspanne: Baseline and post-intervention (week 0 and week 8)
|
Dietary intake was assessed using a 24-hour dietary recall method.
Participants reported all food and beverage consumption over the previous 24 hours, including portion size, preparation methods, meal timing, and eating location.
|
Baseline and post-intervention (week 0 and week 8)
|
|
Stroop Test
Tijdsspanne: baseline and post-intervention (week 0 and week 8)
|
Executive function and inhibitory control were assessed using a standardized colour-word Stroop task administered in paper-based format.
Participants completed a single list of incongruent colour-word stimuli and were instructed to name the ink colour while ignoring the written word.
A brief practice trial was provided prior to testing.
Total completion time (seconds) and number of errors were recorded, with faster completion and fewer errors indicating better performance.
|
baseline and post-intervention (week 0 and week 8)
|
|
Logical Location Test
Tijdsspanne: Baseline and post-intervention (week 0 and week 8)
|
Visuospatial memory was assessed using a 5 × 5 grid-based recall task adapted from established visuospatial memory paradigms.
Participants were presented with a grid containing 10 everyday objects positioned in fixed locations and were given 30 seconds to memorize the arrangement.
The stimulus was then removed, and participants were required to reproduce the object locations.
One point was awarded for each correctly recalled location with higher score indicates better visuospatial memory
|
Baseline and post-intervention (week 0 and week 8)
|
|
Trail Making Test
Tijdsspanne: Baseline and post-intervention (week 0 and week 8)
|
Cognitive processing speed and mental flexibility were assessed using the standard Trail Making Test Parts A and B. The test was administered in paper-based format.
In Part A, participants connected numbers in ascending order, while Part B required alternating between numbers and letters.
Time to completion (seconds) was recorded.
Errors were corrected immediately, and timing continued until completion.
|
Baseline and post-intervention (week 0 and week 8)
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Shi Hui Cheng, University of Nottingham Malaysia
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CSH150725
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .